Figure 2. Effect of anti-IL-2R mAb on anti-CD154 mAb therapy in the C57BL/6 into BALB/c cardiac transplant model. The concomitant use of anti-IL-2R mAb abrogated the effect of single-dose anti-CD154 mAb on cardiac allograft survival (P = .0038 vs. sMR1 alone).